Last updated: 07/17/2024 17:55:54
Pharmacokinetic and Safety Study of Niraparib with Normal or Moderate Hepatic Impairment Patients
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Completed
Completed
Trial overview
Official title: An Open-Label, Non-Randomized, Multicenter Study to Determine the Pharmacokinetics and Safety of Niraparib Following a Single Oral Dose in Patients with Advanced Solid Tumors and Either Normal Hepatic Function or Moderate Hepatic Impairment
Trial description: Niraparib (Zejula®)is extensively metabolized and eliminated primarily by hepatic and renal pathways. The purpose of this study is to evaluate pharmacokinetics and safety of niraparib in patients with moderate hepatic impairment, for the purpose of providing recommendations to guide the initial dose and dose titration in this patient population.
Primary purpose:
Treatment
Trial design:
Parallel Assignment
Masking:
Single (Participant)
Allocation:
Non-randomized
Primary outcomes:
Pharmacokinetic (PK) to be assessed is area under the plasma concentration-time curve from time 0 extrapolated to infinity (AUC0-∞).
Timeframe: Approximately 2 years
Pharmacokinetic (PK) to be assessed is maximum observed plasma concentration (Cmax).
Timeframe: Approximately 2 years
Pharmacokinetic (PK) to be assessed is time to reach Cmax (Tmax).
Timeframe: Approximately 2 years
Pharmacokinetic (PK) to be assessed is termination elimination half-life ( t1/2).
Timeframe: Approximately 2 years
Pharmacokinetic (PK) to be assessed is apparent total body clearance (CL).
Timeframe: Approximately 2 years
Pharmacokinetic (PK) to be assessed is apparent terminal volume of distribution (Vz/F).
Timeframe: Approximately 2 years
Pharmacokinetic (PK) to be assessed is area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration (AUC0-t).
Timeframe: Approximately 2 years
Secondary outcomes:
Evaluate safety and tolerability of niraparib when administered as a single dose in patients with normal hepatic function using Common Terminology Criteria for Adverse Events (CTCAE v.4.03).
Timeframe: Approximately 2 years
Evaluate safety and tolerability of niraparib when administered as a single dose in patients with moderate hepatic impairment using Common Terminology Criteria for Adverse Events (CTCAE v.4.03).
Timeframe: Approximately 2 years
Evaluate safety and tolerability of niraparib in which patients have the option to continue receiving Niraparib using Common Terminology Criteria for Adverse Events (CTCAE v.4.03).
Timeframe: Approximately 2 years
Interventions:
Drug: Niraparib
Enrollment:
17
Observational study model:
Not applicable
Primary completion date:
2019-16-09
Time perspective:
Not applicable
Clinical publications:
Akce M, El-Khouiery A, Piha-Paul S, Bacque E, Pan P, Zhang Z, Ewesuedo R, Gupta D, Tang Y, Milton A, Zajic S, Judson PL, O’Bryant CL. Pharmacokinetics and Safety of Niraparib in Patients with Moderate Hepatic Impairment. Cancer Chemother Pharmacol. 2021;
DOI: 10.1007/s00280-021-04329-8
PMID: 34324028
Medical condition
Ovarian Neoplasms, Neoplasms, Solid Tumor, hepatic impairment
Product
Not applicable
Collaborators
Not applicable
Study date(s)
February 2018 to June 2020
Type
Interventional
Phase
1
Participation criteria
Sex
Female & Male
Age
18+ years
Accepts healthy volunteers
No
- Inclusion Criteria:
- Diagnosis and Criteria for Inclusion:
Inclusion and exclusion criteria
Inclusion criteria:
- Inclusion Criteria: Diagnosis and Criteria for Inclusion: All patients: To be considered eligible to participate in this study, all of the following requirements must be met: 1. Patient, male or female, is at least 18 years of age. 2. Patient has a diagnosis of advanced solid malignancy that has failed standard therapy or for which standard therapy is not likely to provide meaningful benefit, or patient has refused standard therapy. 3. Patient has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1. 4. Patient is able to take oral medications. 5. Female patient, if of childbearing potential, has a negative serum pregnancy test within 72 hours prior to taking study drug and agrees to abstain from activities that could result in pregnancy from enrollment through 120 days after the last dose of study treatment, or be of non-childbearing potential. Non-childbearing potential is defined as (by other than medical reasons):
- ≥45 years of age and has not had menses for > 1 year.
- Amenorrheic for < 2 years without a hysterectomy Post hysterectomy, bilateral oophorectomy, or tubal ligation.. Note: Abstinence is acceptable if this is the established and preferred contraception for the patient. 6. Male patient agrees to use an adequate method of contraception starting with the first dose of study treatment through 120 days after the last dose of study treatment.. 7. Patient is able to understand the study procedures and agrees to participate in the study by providing written informed consent. Patients with normal hepatic function (Group 1): Patients screened for the normal hepatic function group must meet the following additional criteria to be eligible for enrollment: 1. Patient has no history of hepatic impairment. 2. Patient has liver function test (LFT) results within normal range:
- Total bilirubin ≤ ULN
- Aspartate aminotransferase (AST) ≤ ULN.
- INR ≤1.5 X ULN unless the patient is receiving anticoagulant therapy and the INR is within therapeutic range of intended use of anticoagulants. 3. Patient has adequate hematologic and renal function as defined below:
- Absolute neutrophil count ≥1500/µL
- Platelets ≥100,000/µL
- Hemoglobin ≥9 g/dL
- Serum creatinine ≤1.5 × ULN or a calculated creatinine clearance ≥60 mL/min using the Cockcroft-Gault equation. Patients with moderate hepatic impairment (Group 2): Patients screened for the moderate hepatic impairment group must meet the following additional criteria to be eligible for enrollment: 1. Patient has stable, moderate hepatic impairment, defined as:
- BILI: >1.5 × to 3 × ULN, for at least 2 weeks prior to Day 1
- AST: Any value
- INR less than 1.8 unless the patient is receiving anticoagulant therapy and the INR is within therapeutic range of intended use of anticoagulants. 2. Patient has hematologic and renal function as defined below:
- Absolute neutrophil count ≥1000/µL
- Platelets ≥75,000/µL
- Hemoglobin ≥8 g/dL
- Serum creatinine ≤1.5 × ULN or a calculated creatinine clearance ≥60 mL/min using the Cockcroft-Gault equation. 3. Patient's hepatic disease is deemed stable by the Investigator Criteria for Exclusion: Patients will not be eligible for study entry if any of the following criteria are met: All patients: 1. Patient has undergone palliative radiotherapy within 1 week of study drug administration, encompassing >20% of the bone marrow. 2. Patient is starting chemotherapy within 3 weeks of study drug administration. 3. Patient has a known hypersensitivity to the components of niraparib or excipients 4. Patients who received colony-stimulating factors within 2 weeks prior to the first dose of study treatment are not eligible. 5. Patient has persistent chemotherapy associated Grade 2 or greater toxicity except for neuropathy, alopecia or fatigue. 6. Patient has symptomatic uncontrolled brain or leptomeningeal metastases. 7. Patient has undergone major surgery within 3 weeks of starting the study or patient has not recovered from any effects of any major surgery. 8. Patient is considered a poor medical risk due to a serious, uncontrolled medical disorder (other than hepatic impairment) or active, uncontrolled infection. 9. Patient has received a transfusion (platelets or red blood cells) within 3 weeks of receiving niraparib. 10. Patient is pregnant, breastfeeding, or expecting to conceive children while receiving study treatment or for 3 months after the last dose of study treatment. 11. Patient has a known history of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). NOTE: Exclusion Criteria 12-16 apply patients participating in the PK phase of the study. 12. Patient is currently receiving, or unable to refrain from taking from 4 days prior to dosing until the time of the last PK blood draw, any of the following cytochrome (CYP) 1A2 substrates: alosetron, duloxetine, melatonin, ramelteon, tacrine, tizanidine, and theophylline. 13. Patient is unable to refrain from any intake of grapefruit or grapefruit juice within 4 days of the first administration of niraparib until the final PK sample collection. 14. Patient is currently receiving, or unable to refrain from taking from 4 days prior to dosing until the last PK blood draw, any of the following P-glycoprotein (P-gp) inhibitors: amiodarone, azithromycin, captopril, carvedilol, clarithromycin, conivaptan, cyclosporine, diltiazem, dronedarone, erythromycin, felodipine, itraconazole, ketoconazole, lopinavir and ritonavir, quercetin, quinidine, ranolazine, ticagrelor and verapamil. 15. Patient is taking proton pump inhibitors, antacids, or histamine 2 (H2) blockers within 48 hours prior to niraparib administration, and/or within 6 hours after niraparib administration. 16. Patient has esophagogastrointestinal disease or resection that is likely to interfere with the absorption of niraparib. Patients with moderate hepatic impairment (Group 2): Patients screened for the moderate hepatic impairment group who meet any of the following additional criteria will be excluded from the study: 1. Patient has hepatic encephalopathy, severe portal hypertension and/or porto-systemic shunt. 2. Patient has fluctuating or rapidly deteriorating hepatic function as determined by the investigator within the screening period. 3. Patient has acute liver disease caused by drug toxicity or by an infection. 4. Patient has biliary obstruction or other causes of hepatic impairment not related to parenchymal disorder and/or disease of the liver. 5. Patient has esophageal variceal bleeding within the past 2 months. 6. Patient is receiving anticoagulant therapy with warfarin or related coumarins. 7. Patient has a history of hepatic transplant, systemic lupus erythematosus, or hepatic coma.
Trial location(s)
Location
GSK Investigational Site
Atlanta, Georgia, United States, 30322
Status
Study Complete
Location
GSK Investigational Site
Aurora, Colorado, United States, 80045
Status
Study Complete
Location
GSK Investigational Site
Los Angeles, California, United States, 90033
Status
Study Complete
Location
GSK Investigational Site
Newport Beach, California, United States, 92663
Status
Study Complete
Study documents
Clinical study report
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Results posted on ClinicalTrials.gov
Recruitment status
Completed
Actual primary completion date
2019-16-09
Actual study completion date
2020-24-06
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Additional information
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website